PriceTargets.com logo

Revance Therapeutics - RVNC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $39.00
  • Forecasted Upside: 38.15 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$28.23 As of 10/3/2022 01:00 AM ET
▲ +1.23 (4.56%)

This chart shows the closing price for RVNC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Revance Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RVNC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RVNC

Analyst Price Target is $39.00
▲ +38.15% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Revance Therapeutics in the last 3 months. The average price target is $39.00, with a high forecast of $65.00 and a low forecast of $24.00. The average price target represents a 38.15% upside from the last price of $28.23.

This chart shows the closing price for RVNC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Revance Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2022The Goldman Sachs GroupInitiated CoverageBuy$33.00Low
9/9/2022MizuhoBoost TargetBuy$26.00 ➝ $30.00Low
9/9/2022BarclaysBoost TargetOverweight$22.00 ➝ $35.00Low
9/9/2022HC WainwrightBoost TargetBuy$25.00 ➝ $29.00Low
9/8/2022Needham & Company LLCBoost TargetBuy$25.00 ➝ $35.00Low
9/8/2022CowenBoost Target$55.00 ➝ $65.00Low
9/8/2022CowenBoost Target$55.00 ➝ $65.00Low
8/25/2022Wells Fargo & CompanyBoost TargetEqual Weight$17.00 ➝ $24.00Low
8/15/2022GuggenheimBoost Target$35.00Low
8/10/2022HC WainwrightBoost Target$20.00 ➝ $25.00Low
1/19/2022HC WainwrightReiterated RatingBuy$18.00High
10/26/2021BarclaysLower TargetOverweight$33.00 ➝ $22.00Low
10/25/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$35.00 ➝ $17.00Low
10/18/2021Needham & Company LLCLower TargetBuy$45.00 ➝ $25.00High
10/13/2021MizuhoReiterated RatingBuy$36.00Low
10/13/2021HC WainwrightReiterated RatingBuy$35.00 ➝ $26.00High
8/6/2021BarclaysBoost TargetOverweight$32.00 ➝ $33.00High
5/11/2021MizuhoLower TargetBuy$37.00 ➝ $36.00Low
4/23/2021MizuhoBoost TargetBuy$33.00 ➝ $37.00High
4/14/2021Needham & Company LLCReiterated RatingBuy$45.00Medium
2/23/2021MizuhoBoost TargetPositive ➝ Buy$30.00 ➝ $33.00High
2/23/2021HC WainwrightBoost TargetBuy$33.00 ➝ $35.00High
1/8/2021Needham & Company LLCBoost TargetBuy$42.00 ➝ $45.00High
11/10/2020MizuhoLower TargetBuy$32.00 ➝ $30.00High
10/26/2020BarclaysBoost TargetOverweight$35.00 ➝ $38.00Medium
10/15/2020Needham & Company LLCBoost TargetBuy$36.00 ➝ $42.00Low
10/15/2020HC WainwrightBoost TargetBuy$27.00 ➝ $33.00Low
9/28/2020BarclaysBoost TargetOverweight$32.00 ➝ $35.00Low
8/11/2020MizuhoInitiated CoverageBuy$32.00Low
7/10/2020HC WainwrightReiterated RatingBuy$27.00Medium
6/2/2020HC WainwrightReiterated RatingBuy$24.00Medium
5/20/2020MizuhoReiterated RatingBuy$35.00Low
4/16/2020Stifel NicolausLower TargetBuy$35.00 ➝ $31.00High
4/15/2020Needham & Company LLCReiterated RatingBuy$36.00High
4/1/2020MizuhoReiterated RatingBuy$39.00 ➝ $35.00High
3/27/2020William BlairReiterated RatingBuyMedium
3/27/2020HC WainwrightReiterated RatingBuy$28.00 ➝ $24.00Medium
3/22/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$32.00 ➝ $15.00Medium
2/26/2020HC WainwrightReiterated RatingBuy$23.00 ➝ $28.00Low
2/25/2020Piper SandlerBoost TargetOverweight$37.00 ➝ $40.00High
2/25/2020Needham & Company LLCBoost TargetBuy$32.00 ➝ $36.00High
2/18/2020Piper SandlerLower TargetOverweight$38.00 ➝ $37.00Low
1/23/2020MizuhoBoost TargetBuy ➝ Positive$34.00 ➝ $39.00Low
12/2/2019The Goldman Sachs GroupInitiated CoverageBuy$25.00High
11/5/2019MizuhoReiterated RatingBuy$34.00High
10/30/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$12.50 ➝ $20.00High
10/15/2019HC WainwrightSet TargetBuy$23.00Medium
10/14/2019MizuhoReiterated RatingBuy$34.00High
8/6/2019William BlairReiterated RatingOutperformHigh
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$28.00Medium
4/24/2019MizuhoReiterated RatingBuy$37.00Medium
3/1/2019SunTrust BanksLower TargetPositive ➝ Buy$29.00High
2/27/2019MizuhoReiterated RatingBuyHigh
2/15/2019Wells Fargo & CompanyInitiated CoverageMarket Perform$17.83Low
2/14/2019HC WainwrightInitiated CoverageBuy$25.00Low
1/28/2019Stifel NicolausInitiated CoverageBuy$50.00High
1/18/2019MizuhoReiterated RatingBuyMedium
11/16/2018GuggenheimUpgradeNeutral ➝ Buy$41.00Low
11/1/2018Cantor FitzgeraldReiterated RatingBuy$50.00High
9/17/2018Piper Jaffray CompaniesReiterated RatingBuyLow
9/17/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
9/14/2018Cantor FitzgeraldReiterated RatingBuy$50.00Low
8/2/2018Cantor FitzgeraldSet TargetBuy$50.00High
5/29/2018Cantor FitzgeraldSet TargetBuy$50.00High
5/8/2018Cantor FitzgeraldSet TargetBuy$50.00High
4/20/2018GuggenheimReiterated RatingHoldHigh
4/20/2018MizuhoLower TargetBuy$54.00 ➝ $48.00High
4/2/2018Cantor FitzgeraldReiterated RatingBuy$50.00Medium
3/26/2018Needham & Company LLCInitiated CoverageBuy$42.00Low
3/5/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$60.00Medium
3/1/2018Piper Jaffray CompaniesSet TargetBuy$48.00High
3/1/2018William BlairReiterated RatingOutperformMedium
2/28/2018Cantor FitzgeraldSet TargetBuy$50.00Medium
1/17/2018CowenSet TargetBuy$55.00Low
1/9/2018GuggenheimDowngradeBuy ➝ HoldN/A
1/5/2018MizuhoReiterated RatingBuy$54.00Low
1/4/2018GuggenheimReiterated RatingBuy ➝ Neutral$42.00High
1/4/2018Cantor FitzgeraldSet TargetBuy$50.00Low
12/19/2017BarclaysSet TargetOverweight ➝ Buy$40.00High
12/13/2017Cantor FitzgeraldSet TargetBuy$50.00Low
12/8/2017SunTrust BanksBoost TargetBuy$53.00Medium
12/6/2017MizuhoBoost TargetBuy ➝ Buy$37.00 ➝ $54.00Medium
12/5/2017GuggenheimInitiated CoverageBuy ➝ Buy$42.00Medium
12/5/2017Piper Jaffray CompaniesBoost TargetPositive ➝ Overweight$28.00 ➝ $51.00High
12/5/2017Cantor FitzgeraldSet TargetBuy$50.00High
11/29/2017Cantor FitzgeraldSet TargetBuy$50.00High
11/27/2017BarclaysInitiated CoverageOverweight$31.00Medium
11/16/2017Cantor FitzgeraldSet TargetBuy$50.00N/A
11/16/2017MizuhoInitiated CoverageBuy ➝ Buy$37.00N/A
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$28.00N/A
10/24/2017Cantor FitzgeraldSet TargetBuy$50.00N/A
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/5/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/4/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2022
  • 10 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022

Current Sentiment

  • 10 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Revance Therapeutics logo
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Read More

Today's Range

Now: $28.23
Low: $26.79
High: $28.37

50 Day Range

MA: $22.10
Low: $15.52
High: $28.47

52 Week Range

Now: $28.23
Low: $11.27
High: $29.51

Volume

1,789,961 shs

Average Volume

2,484,406 shs

Market Capitalization

$2.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Revance Therapeutics?

The following Wall Street sell-side analysts have issued reports on Revance Therapeutics in the last year: Barclays PLC, Cowen Inc, Cowen Inc., Guggenheim, HC Wainwright, Mizuho, Needham & Company LLC, StockNews.com, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for RVNC.

What is the current price target for Revance Therapeutics?

9 Wall Street analysts have set twelve-month price targets for Revance Therapeutics in the last year. Their average twelve-month price target is $39.00, suggesting a possible upside of 38.2%. Cowen Inc. has the highest price target set, predicting RVNC will reach $65.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $24.00 for Revance Therapeutics in the next year.
View the latest price targets for RVNC.

What is the current consensus analyst rating for Revance Therapeutics?

Revance Therapeutics currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RVNC will outperform the market and that investors should add to their positions of Revance Therapeutics.
View the latest ratings for RVNC.

What other companies compete with Revance Therapeutics?

Other companies that are similar to Revance Therapeutics include Schrödinger, Axsome Therapeutics, Ventyx Biosciences, Supernus Pharmaceuticals and Cassava Sciences. Learn More about companies similar to Revance Therapeutics.

How do I contact Revance Therapeutics' investor relations team?

Revance Therapeutics' physical mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company's listed phone number is (615) 724-7755 and its investor relations email address is [email protected] The official website for Revance Therapeutics is www.revance.com. Learn More about contacing Revance Therapeutics investor relations.